MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.

@article{Ossowska2005MTEPAN,
  title={MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.},
  author={Krystyna Ossowska and Jolanta Konieczny and Stanisław Wolfarth and Andrzej Pilc},
  journal={Neuropharmacology},
  year={2005},
  volume={49 4},
  pages={447-55}
}
The aim of the present study was to examine a potential antiparkinsonian-like action of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP), a new non-competitive antagonist of mGluR5, in the rat models. This compound has affinity for mGluR5 in a nanomolar concentration range and seems to be superior to the earlier known antagonists in terms of its specificity and bioavailability. Catalepsy and muscle rigidity induced by haloperidol administered at doses of 0.5 and 1 mg/kg were regarded as… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Mavoglurant as a treatment for Parkinson's disease.

Expert opinion on investigational drugs • 2014
View 3 Excerpts

Similar Papers

Loading similar papers…